ORYZON appoints Eisai executive Vanessa Almendro Navarro to Board of Directors


• Dr. Vanessa Almendro Navarro, PhD, MBA, is Director of Strategy and Operations at EISAI's Genetic Guided Discovery in Dementia (G2D2) Center in Boston

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Vanessa Almendro Navarro, of Eisai US, as an independent director. Dra. Almendro will be Lead Director and member of the Remuneration and Nomination Committee.


Click here to see the full Press Release